PepsiCo, Inc. vs Smith & Nephew plc — how do they compare? PepsiCo, Inc. trades at $137.31 (market cap $188.97B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: PepsiCo, Inc. is far larger — about 16.2× Smith & Nephew plc's market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| PEP | SNN | |
|---|---|---|
Market Cap | $188.97B | $11.63B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $38.53 |
52-Week Low | $134.95 | $27.80 |
Enterprise Value | $231.47B | $14.66B |
Dividend Yield | 4.28% | 2.85% |
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income declined to $8.24B. Analysts maintain a consensus price target of $158.79 with 33% buy ratings. Recent news highlights price adjustments on snack products and sponsorship changes.
PEP offers stable dividend income and moderate growth potential, but faces margin pressure from input costs and competitive pricing. The stock trades below analyst targets with solid cash flow generation, though technical indicators suggest near-term weakness. Key risks include consumer sensitivity to price increases and execution challenges in North American markets.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →